Impressive news from BIXT today. This company is making major advances that apply to the critical area of stroke treatment and also a range of related medical issues.
Note the direct comments from CEO David Platt the announcement:
“Measuring the level of tissue oxygenation in diseases and surgical procedures could have a profound effect in clinical research” said Dr David Platt, CEO of Bioxytran. “In the past, researchers trying to prove the efficacy of a procedure on a vital organ like the brain had to rely on surrogate markers such as cognitive tests which require large patient populations and relatively subjective tests. With the advent of the FDA approved MDX Viewer, researchers can now accelerate their studies using the TMS biomarker and likely save a lot of money in the process. Tissue oxygenation levels are also important in tissue regeneration, stem cell transplantation, tissue transplantation, and tissue viability. The licensing opportunities in this area are boundless. Bioxytran’s initial focus will be for patients of a stroke, Acute Respiratory Deficiency Syndrome (ARDS), sepsis, and heart failure. The stroke market is estimated at 900,000 annually. Since there is an unmet medical need in the stroke indication, Bioxytran will be primarily focusing its efforts in advancing BXT-25 through the clinical trials.”
News 
Market Data 
Discover 
